4d
Engineering Software · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Parc Les Erables Btiment 4, Le Pecq, le-...Phone Number
+33 130539200Website
www.4d.comRevenue
$32.9 MillionIndustry
About 4d
4d Org Chart
Is 4d your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once 4d has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when 4d launches new products
Check if 4d has recently received funding, and reach out quickly before it becomes old news!
4d, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on 4d recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at 4d
Check out if 4d is spiking on competitors!
Click to see if 4d had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
4d is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
4d is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about 4d.
4d Tech Stack
A closer look at the technologies used by 4d
4d News & Media
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met itRaySecur Receives $1M NSF Grant to Develop AI Threat Detection Software for MailSecur Scanners
CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- RaySecur™, a security imaging company with the world's first DHS Safety Act-designated T-ray desktop scanner for mail and package threat detection, today announced it has been awarded a Phase II grant from the National Science Foundation...4D pharma to Present at the H.C. Wainwright BioConnect Conference
LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer of 4D pharma, and Alex Stevenson, Chief Scientific Officer of 4D pharma, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting Monday, January 10, 2022 at4D pharma appoints John Doyle as Chief Financial Officer - OneAd Blog
Leeds, England - (work wire) -4D Pharma plc (AIM: DDDD, NASDAQ: LBPS)The pharmaceutical company leading the development of live biotherapy products (LBPs), a
Top Engineering Software Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding 4d
4D's mission is straightforward: To simplify and speed up business application development and deployment. They do this by offering developers and end-users a powerful, integrated platform that embraces open standards and forward-looking technologies while remaining compatible with existing systems. 4D has been doing this for small-to-medium busine... Read More